06-06-2013 дата публикации
Номер: US20130142795A1
Provided are a fusion protein of Exendin-4 and its analog, the preparation method and use thereof. The fusion protein is obtained by fusing of Exendin-4 or its analog to Fc region of human IgG2 via a linking peptide, which has the better stability and prolonged serum half-life, and can be used for treating diabetes and obesity. 1. A fusion protein , which is obtained by fusing peptide hormone to transport protein via linker , wherein , the said peptide hormone is Exendin-4 or analogue of Exendin-4 , and the said peptide hormone is capable of lowering the blood glucose; the said transport protein is the Fc fragment of the immunoglobulin IgG2; the said fusion protein is capable of lowering the blood glucose; {'br': None, 'sup': 2', '10', '12', '13', '14', '19', '20', '21', '24', '27', '28', '30', '31', '32', '33', '34', '35', '36', '37', '38', '39, 'His-Xaa-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Xaa-Ser-Xaa-Xaa-Xaa-Glu-Glu-Glu-Ala-Xaa-Xaa-Xaa-Phe-Ile-Xaa-Trp-Leu-Xaa-Xaa-Gly-Xaa-Xaa-Xaa-Xaa-Xaa-Xaa-Xaa-Xaa-Xaa-Xaa\u2003\u2003Formula I'}, 'the said peptide hormone comprises the sequence shown by Formula IWherein:{'sup': '2', 'Xaais Gly, Thr, Ala, Ser, Leu, Ile or Lys;'}{'sup': '10', 'Xaais Leu, Ala, Ser, Leu, Ile, Glu or Lys;'}{'sup': '12', 'Xaais Lys, Leu, Thr, Ser, Leu, Ile or Cys;'}{'sup': '13', 'Xaais Gln, Thr, Ala, Val, Leu, Ile or Lys;'}{'sup': '14', 'Xaais Met, Tyr, Thr, Ala, Ser, Ile or Lys;'}{'sup': '19', 'Xaais Val, Cys, Ala, Ser, Leu, Ile or Lys;'}{'sup': '20', 'Xaais Arg, Thr, Tyr, Ser, Leu, Ile or Lys;'}{'sup': '21', 'Xaais Leu, Thr, Ala, Asp, Glu, His or Lys;'}{'sup': '24', 'Xaais Glu, Leu, Thr, Ala, Ser, Lys or Ile;'}{'sup': '27', 'Xaais Lys, Ala, Ser, Leu, Thr, Ile or Lys;'}{'sup': '28', 'Xaais Asp, Thr, Ala, Ser, Leu, Ile or Lys;'}{'sup': '30', 'Xaais Gly, Thr, Ala, Ser, Leu, Ile or Arg;'}{'sup': '31', 'Xaais Pro, Val, Ser, Ala, Leu, Ile or Lys;'}{'sup': '32', 'Xaais Ser, Thr, Glu, Ser, Asp, Lys or Ile;'}{'sup': '33', 'Xaais Thr, Ser, Ala, Met, Leu, Ile or Lys ...
Подробнее
